{"name":"Se-Hoon Lee","slug":"se-hoon-lee","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Atezolizumab, Etoposide, Carboplatin, Tarlatamab","genericName":"Atezolizumab, Etoposide, Carboplatin, Tarlatamab","slug":"atezolizumab-etoposide-carboplatin-tarlatamab","indication":"Non-small cell lung cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Lazertinib group","genericName":"Lazertinib group","slug":"lazertinib-group","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Atezolizumab, Etoposide, Carboplatin, Tarlatamab","genericName":"Atezolizumab, Etoposide, Carboplatin, Tarlatamab","slug":"atezolizumab-etoposide-carboplatin-tarlatamab","phase":"phase_2","mechanism":"PD-L1 inhibitor","indications":["Non-small cell lung cancer","Urothelial carcinoma","Triple-negative breast cancer"],"catalyst":""},{"name":"Lazertinib group","genericName":"Lazertinib group","slug":"lazertinib-group","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNQ01Zb0xJMDVyZUx2alU1TkNVZy1jWVk5MjJaUEpqeTRsM20teHcxb1hZUHhaN3RkOFd5Tm16c2JPX3VORXVzNFAtS19oMkJBWmJjNE9aQXRMMEJnQkUzc21LRTVwT3Z5MjVYLW5GQnBIbWdnS2JqeDMzSXZ6UktIRnhjdUU0ZjRiYlVTTjl0SQ?oc=5","date":"2026-03-17","type":"trial","source":"Yahoo Finance","summary":"Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody - Yahoo Finance","headline":"Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOZ0xzRVF0TTJsaFdGR3dZQjNtWXp0NDhIY2hLR3laUHhoV3l4Z3pRNVpqTE5aUzlDSWdLYnlpY1pjQ244dUI1amF5N2Jfb1FiMXVHRWdOSTdlcF9YSVBCejZ6Z3NPZzZFR2I3Q2Z3dGVJc2UtUlZSV0lrZXpPWHNRWm05blRiRXhNcW5Oa2h3VW5tNFJYY2VvQjRTRGl1STlMUU1MMFREbmNhS2JpMHgzcFRSNklnNnJGeUNWY0tmNA?oc=5","date":"2026-03-17","type":"trial","source":"Stock Titan","summary":"New 'don't-eat-me' cancer antibody to be tested in Liminatus lung trial - Stock Titan","headline":"New 'don't-eat-me' cancer antibody to be tested in Liminatus lung trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1YbkZNX1BhcW5hRk1JRkNCYjJUbEFtYzJIYzVTd0NBb3FGdno3V0JlNHpHdTl5eHFMWjBJR1QzamNWZDdpMjRDc2prR0VPX0toRkdmZmstczZTQkVBYVlocUt4Q2F2NHU0X2lkalJR0gFyQVVfeXFMTmpDZTlteFJXZ19HT0JhWTR5WUlyNERvRnhtZkUtLWt6SFRkOTV3VUk3SWxqNEswZzJ1TXRiaFFOdnAwNGpCSUJoV2c1QWtvbjlUMXIyNVpxZXhZNW1CazZrRG5rMXdhTGpXaDdPZWJabnFB?oc=5","date":"2024-05-24","type":"pipeline","source":"koreabiomed.com","summary":"‘Keytruda redefined concept of early-stage lung cancer treatment’ - koreabiomed.com","headline":"‘Keytruda redefined concept of early-stage lung cancer treatment’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFA2di1ITjJNZmEwV3A0QVBYSnREdEsxdDFHVGVpRllxYV81QXUtdkh1TE45bzYzeVBMbWJ1NkV5ZW9DbjUxenRNOHh1RndMQ000YVZhZkVOR25hMFhySjZvVEpNdEg5MW1WWDJDMkxrbm94ZllkQ2dJZkhBcw?oc=5","date":"2024-01-02","type":"pipeline","source":"Wiley","summary":"Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non–small cell lung cancer patients with chronic hepatitis B - Wiley","headline":"Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non–s","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}